Patient at facility A with a lower respiratory infection 3 months after a heart transplant
Respiratory cultures revealed a carbapenem resistant A. baumannii
Treatment:
Polymixin-B
Meropenem
Colistin
Cefiderocol as compassionate treatment
Patient passed away, unclear if cause was sepsis
5 additional patients from Facility A had sputum cultures that were positive for carbapenem resistant A. baumannii
Wisconsin State Laboratory of Hygiene
Antimicrobial susceptibility
Amikacin: Resistant
Aztreonam: Resistant
Cefepime: Resistant
Cefotaxime: Resistant
Ceftazidime: Resistant
Ciprofloxacin: Resistant
Colistin: Susceptible
Doripenem: Resistant
Doxycycline: Resistant
Gentamicin: Resistant
Imipenem: Resistant
Levofloxacin: Resistant
Meropenem: Resistant
Minocycline: Intermediate
Piperacillin-tazobactam: Resistant
Polymyxin-B: Susceptible
Ticarcillin-clavulanate: Resistant
Tobramycin: Resistant
Trimethoprim-sulfamethoxazole: Resistant
Case Definitions
Probable
Carbapenem resistant A. baumannii clinical isolate with outbreak AST profile
Confirmed
Carbapenem resistant A. baumannii clinical isolate genetically clustering with other outbreak isolates and harboring the OXA-24/40-like β-lactamase OXA-72
Case Definitions
Probable (n=43)
Carbapenem resistant A. baumannii clinical isolate with outbreak AST profile
Confirmed (n=22)
Carbapenem resistant A. baumannii clinical isolate genetically clustering with other outbreak isolates and harboring the OXA-24/40-like β-lactamase OXA-72
Summary
Next Generation Genomic Data is already large and growing with new technology
Critical reductions in time to result with genomic data to better inform public health policy and interventions
Infrastructure needs flexibility to adapt to changes in demand with the potential for high demand
Genomic data is a unique data type that doesn't fit with typical data solutions